Home › NDC Lookup › Ingredients › Olopatadine Hydrochloride Ophthalmic › 43598-0764-02
👁️image loading
(from DailyMed)

Olopatadine Hydrochloride Ophthalmic Solution 2 mg/mL Solution, 1 bottle — NDC 43598-764-02 (Billing 43598-0764-02)

by Dr. Reddy's Laboratories Inc. · 1 BOTTLE, PLASTIC in 1 CARTON / 2.5 mL in 1 BOTTLE, PLASTIC

This is a package of 1 bottle of Olopatadine Hydrochloride Ophthalmic Solution 2 mg/mL Solution from Dr. Reddy's Laboratories Inc., marketed since Sep 2020 and currently FDA-listed; retail pharmacies pay about $2.96 per mL (NADAC). It is the main listing for this product, which comes in 3 package sizes.

NDC 43598-0764-02
🏷️ FDA NDC (as labeled) 43598-764-02 billing pads the product segment with a zero
This package
Contains1 bottle Cost per mL$2.96 NADAC Per package$7.41 / 2.5 ml Pack sizes3 compare ↓
Also priced by: Medicaid pays $6.05/unit — full pricing hub ↓
Main listing for product 43598-764 · Also comes in: 2 bottles 43598-764-25 1000 bottles 43598-764-10
OTC Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 43598-764-02
Product NDC 43598-764
11-digit billing NDC 43598076402
NCPDP billing unit ML — per mL (volume)
RxCUI 1111343
UNII 2XG66W44KF
Application # ANDA209752
SPL Set ID f249d79e-0f62-d2f1-bcbc-22dda253aad2
Established class (EPC) Histamine-1 Receptor Antagonist; Histamine-1 Receptor Inhibitor; Mast Cell Stabilizer
Mechanism of action Histamine H1 Receptor Antagonists
Physiologic effect Decreased Histamine Release
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2020-09-01
Route OPHTHALMIC
Dosage form SOLUTION
Substance OLOPATADINE HYDROCHLORIDE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 86802065102030
GPI class Olopatadine HCl
GCN Seq No 062065
GCN 97848
HICL code 012815
Ingredient (HICL) Olopatadine Hcl
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q6
Therapeutic class — intermediate (HIC2) Ophthalmic Preparations
HIC3 code Q6R
Therapeutic class — specific (HIC3) Eye Antihistamines
AHFS code 52:02.00.00
AHFS class Antiallergic Agents
FDB label name OLOPATADINE HCL 0.2% EYE DROP
FDB brand name Olopatadine Hcl
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 062065
  • GCN: 97848
  • GPI-14 (Medi-Span): 86802065102030
  • HICL (First Databank): 012815
  • AHFS class code: 52:02.00.00
  • RxCUI (RxNorm): 1111343
Why two NDCs? The FDA registers this code as 43598-764-02 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 43598-0764-02. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Histamine-1 Receptor Inhibitor class.

Pharmacologic class Histamine-1 Receptor Inhibitor, Histamine-1 Receptor Antagonist, Mast Cell Stabilizer
Drug family (ATC) Antiallergic agents, excl. corticosteroids, Other antiallergics
How it works Histamine H1 Receptor Antagonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name OLOPATADINE HCL 0.2% EYE DROP Ingredient Olopatadine Hcl
📗 Our plain-language guide HelloPharmacist
  • The eye drops relieve itchy eyes from allergies, and some products relieve redness too. The nasal spray relieves seasonal allergic rhinitis symptoms in adults and children 6 and ol...
  • It depends on the product. Some eye drops are twice daily, 6 to 8 hours apart, and others once daily. The nasal spray is twice daily. Follow your label or prescriber.
  • Take your lenses out before using the drops and wait at least 10 minutes before putting them back. Don't wear lenses if your eyes are red. These drops aren't for contact lens irrit...
  • With the nasal spray, a bitter taste, headache, nosebleeds and sore throat are common. It can also make you drowsy, so be careful driving and skip alcohol.
📖 Read our full Olopatadine guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $2.964 $7.41 / 2.5 ml
Medicaid paysCMS SDUD · 12 mo $6.05 $15.12 / 2.5 ml
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per mL) — tap or hover for the price & month
Dec 2023 Jan 2026 May 2026 Sep 2026 $3.397 $2.964
▼ Down 11% over the last 13 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
43598-0764-02 You're viewing this Main listing 1 BOTTLE, PLASTIC in 1 CARTON / 2.5 mL in 1 BOTTLE, PLASTIC $2.96 / mL $7.41 2020-09-01 — Active
43598-0764-25 43598-764-25 2 BOTTLE, PLASTIC in 1 CARTON / 2.5 mL in 1 BOTTLE, PLASTIC — — 2020-09-01 — Active
43598-0764-10 43598-764-10 1000 BOTTLE, PLASTIC in 1 CASE / 2.5 mL in 1 BOTTLE, PLASTIC — — — — Active

In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package contains 1 bottle — 1 bottle, plastic in 1 carton / 2.5 ml in 1 bottle, plastic.
How does this package differ from NDC 43598-0764-25?
Both are Olopatadine Hydrochloride Ophthalmic Solution 2 mg/mL Solution — the drug itself is identical. This page's package is the 1 bottle one, while NDC 43598-0764-25 is the 2 bottles package.
What NDC number is used to bill for this package of Olopatadine Hydrochloride Ophthalmic Solution 2 mg/mL Solution?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Olopatadine Hydrochloride 2 mg/mL 24208-0617-01 Bausch 1 bottle $1.983 — Availability likely save 33%
Leader Olopatadine Hydrochloride 2 mg/mL 70000-0716-01 CARDINAL 1 bottle $1.983 — Availability likely save 33%
Olopatadine Hydrochloride 2 mg/mL 00536-1307-23 Rugby 1 bottle $2.964 — Availability likely —
olopatadine hydrochloride 2 mg/mL 16571-0861-25 Rising 2.5 ml $2.964 — Availability likely —
Olopatadine Hydrochloride Ophthalmic Solution 2 mg/mLthis 43598-0764-02 Dr. 1 bottle $2.964 — Availability likely —
Olopatadine Hydrochloride 2 mg/mL 46122-0671-27 Amerisource 1 bottle $2.964 — Availability likely —
Olopatadine Hydrochloride 2 mg/mL 68001-0530-69 BluePoint 1 bottle $2.964 — Availability likely —
Olopatadine Hydrochloride 2 mg/mL 68001-0674-92 BluePoint 1 bottle $2.964 — Availability likely —
Olopatadine Hydrochloride 2 mg/mL 70069-0491-01 Somerset 1 bottle $2.964 — Availability likely —
Eye Allergy Itch Relief Once Daily Relief 2 mg/mL 70677-1155-01 Strategic 1 bottle $2.964 — Availability likely —
Olopatadine Hydrochloride Ophthalmic Solution 2 mg/mL 83324-0120-25 Chain 1 bottle $2.964 — Availability likely —
Eye Allergy Itch Relief 2 mg/mL 70000-0053-01 CARDINAL 1 bottle $3.096 — Availability likely +4%
Pataday Once Daily Relief 2 mg/mL 00065-8150-01 Alcon 1 bottle $5.893 — Availability likely +99%
Olopatadine Hydrochloride 2 mg/mL 00363-0869-01 WALGREEN 1 bottle — — FDA listed —
Olopatadine Hydrochloride Ophthalmic Solution 2 mg/mL 00363-7131-25 Walgreens 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 00363-8022-39 WALGREEN 1 bottle — — FDA listed —
Olopatadine Hydrochloride Ophthalmic Solution 2 mg/mL 11673-0688-25 Target 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 11822-0063-02 RITE 1 bottle — — FDA listed —
Olopatadine Hydrochloride Ophthalmic Solution 2 mg/mL 11822-9975-02 Rite 1 bottle — — FDA listed —
Olopatadine Hydrochloride Ophthalmic Solution 2 mg/mL 21130-0105-02 Albertsons 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 24208-0967-01 Bausch 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 30142-0026-27 Kroger 1 bottle — — FDA listed —
Once Daily Relief 2 mg/mL 37808-0045-25 H 1 bottle — — FDA listed —
Eye Allergy Itch Relief Once Daily Relief 2 mg/mL 43598-0827-02 Dr. 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 46122-0824-29 AmerisourceBergen 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 46708-0710-03 Alembic 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 50090-5613-00 A-S 1 bottle — — FDA listed —
Allergy Relief Eye Drops 2 mg/mL 51316-0675-25 CVS 1 bottle — — FDA listed —
Retaine Allergy 5 mg/2.5mL 54799-0920-25 OCuSOFT 2.5 ml — — FDA listed —
Olopatadine Hydrochloride Ophthalmic Solution Once Daily 2 mg/mL 55910-0137-25 DOLGENCORP, 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 58602-0007-39 Aurohealth 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 58602-0010-39 Aurohealth 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 58602-0013-39 Aurohealth 1 bottle — — FDA listed —
Olopatadine hydrochloride 2 mg/mL 60505-6222-02 Apotex 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 62332-0502-03 Alembic 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 62332-0710-03 Alembic 1 bottle — — FDA listed —
Olopatadine Hydrochloride Ophthalmic Solution 2 mg/mL 63868-0821-25 Chain 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 63941-0024-39 Best 1 bottle — — FDA listed —
Olopatadine Hydrochloride Ophthalmic 2 mg/mL 68083-0231-01 Gland 1 bottle — — FDA listed —
Eye Allergy Itch Relief 2 mg/mL 69168-0495-77 Allegiant 2 bottles — — FDA listed —
CVS Eye Allergy Itch Relief Once Daily 2 mg/mL 69842-0269-25 CVS 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 72036-0009-39 Harris 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 72476-0851-21 Retail 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 72657-0194-11 GLENMARK 2 bottles — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 73581-0709-02 YYBA 2 bottles — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 76162-0044-39 TOPCO 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 79481-1001-02 Meijer 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 79903-0001-39 Wal-Mart 1 bottle — — FDA listed —
Equate Olopatadine Hydrochloride 2 mg/mL 79903-0318-01 WAL-MART 1 bottle — — FDA listed —
Olopatadine Hydrochloride 2 mg/mL 80539-0001-39 Allwell 1 bottle — — FDA listed —
Olopatadine Hydrochloride Ophthalmic Solution 2 mg/mL 82442-0967-02 TARGET 1 bottle — — FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2020
On the market since
Sep 2020
📍
2026
Currently FDA-listed
6 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII F5UM2KM3W7
    Benzalkonium chloride is a chemical compound that works as a preservative and antimicrobial agent in medications. It prevents bacterial and fungal growth in liquid formulations to keep the product safe during storage and use.
  • UNII 7FLD91C86K
    Edetate disodium is a chemical compound that binds and removes certain metal ions. In medicines, it acts as a preservative and stabilizer by preventing metals like calcium from interfering with the product's shelf life and consistency.
  • UNII QTT17582CB
    A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
  • UNII U725QWY32X
    Povidone K30 is a synthetic polymer made from petroleum. It acts as a binder to hold tablet ingredients together and as a disintegrant to help the tablet break apart in the stomach so the medicine can be absorbed.
  • UNII 451W47IQ8X
    Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
  • UNII 55X04QC32I
    A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
  • UNII 22ADO53M6F
    A mineral salt derived from phosphoric acid, used as a buffer to maintain the pH balance of the medication and help stabilize the active ingredients.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

8 inactive ingredients listed in the exact product block matched to this NDC.

The official label also statesBenzalkonium chloride 0.01%, Dibasic sodium phosphate, Edetate disodium, Hydrochloric acid/Sodium hydroxide (adjust pH), Povidone, Sodium chloride, and Water for Injection.

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerDr. Reddy's Laboratories Inc.
Application holderGLAND PHARMA LTD
FDA applicationANDA209752 (ANDA)
Labeler code43598
First marketedSep 2020
Product typeHuman Otc Drug
Portfolio160 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 📄 Do Not Use 📄 When Using This Product 📄 Stop Use and Ask a Doctor If 📄 Keep Out of Reach of Children 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 14 words ▾

USE temporarily relieves itchy eyes due to pollen, ragweed, grass, animal hair and dander

⏱️ Dosage and Administration 56 words ▾

DIRECTIONS adults and children 2 years of age and older: put 1 drop in the affected eye(s) once daily, no more than once per day if using other ophthalmic products while using this product, wait at least 5 minutes between each product replace cap after each use children under 2 years of age: consult a doctor

⚠️ Warnings 5 words ▾

WARNINGS For external use only

🧪 Active Ingredient 9 words ▾

ACTIVE INGREDIENT Olopatadine (0.2%) (equivalent to olopatadine hydrochloride 0.222%)

🧪 Inactive Ingredients 22 words ▾

INACTIVE INGREDIENTS Benzalkonium chloride 0.01%, Dibasic sodium phosphate, Edetate disodium, Hydrochloric acid/Sodium hydroxide (adjust pH), Povidone, Sodium chloride, and Water for Injection.

🎯 Purpose 2 words ▾

PURPOSE Antihistamine

📄 Do Not Use 26 words ▾

DO NOT USE if solution changes color or becomes cloudy if you are sensitive to any ingredient in this product to treat contact lens related irritation

📄 When Using This Product 43 words ▾

WHEN USING THIS PRODUCT do not touch tip of container to any surface to avoid contamination remove contact lenses before use wait at least 10 minutes before reinserting contact lenses after use do not wear a contact lens if your eye is red

📄 Stop Use and Ask a Doctor If 27 words ▾

STOP USE AND ASK DOCTOR IF you experience: eye pain changes in vision increased redness of the eye itching worsens or lasts for more than 72 hours

📄 Keep Out of Reach of Children 19 words ▾

KEEP OUT OF REACH OF CHILDREN If swallowed, get medical help or contact a Poison Control Center right away.

📄 Package Label / Principal Display Panel 22 words ▾

PRINCIPAL DISPLAY PANEL NDC 68083-231-01 Olopatadine Hydrochloride Ophthalmic Solution, USP 0.2% Bottle Label: Olopatadine Hydrochloride Ophthalmic Solution, USP 0.2% C arton Label:

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
25.4K
Units reimbursed last 4 qtrs
72.8K
Gross reimbursed last 4 qtrs
$440.2K
Avg / prescription
$17.34
Avg / unit
$6.0474
Latest quarter Q1 2026
4.8KRx
Medicaid pays / mL
$6.0474
gross reimbursed
vs
NADAC / mL
$2.9636
acquisition cost
=
Spread
+$3.0838
+104% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
74% FFS 26% MCO
Fee-for-service · 18,664 Rx Managed care · 6,726 Rx
State Medicaid map
Alaska: 30 units · 4.1 per 100k residents AK Maine: 33 units · 2.4 per 100k residents ME Washington: no data reported WA Idaho: 128 units · 6.5 per 100k residents ID Montana: 43 units · 3.8 per 100k residents MT North Dakota: no data reported ND Minnesota: 1,797 units · 31.3 per 100k residents MN Wisconsin: 2,663 units · 45.1 per 100k residents WI Michigan: 1,575 units · 15.7 per 100k residents MI New York: 23,886 units · 122 per 100k residents NY Vermont: 60 units · 9.3 per 100k residents VT New Hampshire: no data reported NH Oregon: 153 units · 3.6 per 100k residents OR Nevada: 168 units · 5.3 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: 340 units · 5.0 per 100k residents IN Ohio: 4,205 units · 35.7 per 100k residents OH Pennsylvania: 5,215 units · 40.2 per 100k residents PA New Jersey: 610 units · 6.6 per 100k residents NJ Massachusetts: no data reported MA California: 19,348 units · 49.7 per 100k residents CA Utah: no data reported UT Colorado: 508 units · 8.6 per 100k residents CO Nebraska: 868 units · 43.9 per 100k residents NE Missouri: 3,170 units · 51.2 per 100k residents MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: 1,040 units · 11.9 per 100k residents VA Maryland: 383 units · 6.2 per 100k residents MD Connecticut: 1,308 units · 36.2 per 100k residents CT Rhode Island: 28 units · 2.6 per 100k residents RI Arizona: 130 units · 1.7 per 100k residents AZ New Mexico: no data reported NM Kansas: 278 units · 9.5 per 100k residents KS Arkansas: no data reported AR Tennessee: 1,243 units · 17.4 per 100k residents TN North Carolina: 1,448 units · 13.4 per 100k residents NC South Carolina: 738 units · 13.7 per 100k residents SC Delaware: 273 units · 26.5 per 100k residents DE Oklahoma: no data reported OK Louisiana: 30 units · 0.7 per 100k residents LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: 200 units · 1.8 per 100k residents GA D.C.: no data reported DC Hawaii: 268 units · 18.7 per 100k residents HI Texas: no data reported TX Florida: 635 units · 2.8 per 100k residents FL
Units reimbursed · per 100k residents
0.7122
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New York 122 /100k
2 Missouri 51.2 /100k
3 California 49.7 /100k
4 Wisconsin 45.1 /100k
5 Nebraska 43.9 /100k
6 Pennsylvania 40.2 /100k
7 Connecticut 36.2 /100k
8 Ohio 35.7 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 bottle this page43598-0764-02 25,390 Rx · $440,212
2 bottles43598-0764-25 No Medicaid data
1000 bottles43598-0764-10 No Medicaid data
Drug total (last 4 qtrs): 25,390 Rx · 72,793 units · $440,212 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Olopatadine Hydrochloride Ophthalmic Solution (this brand).

Top reported reactions

Treatment Failure1,933
Nausea117
Headache116
Diarrhoea114
Fatigue103
Pneumonia103
Pyrexia102

Reporter sex

4,003 reports
Male · 32%
Female · 68%
Unknown · 0%

Serious outcomes

Hospitalization774
Death192
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 1,938 132
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
← 43598-0759-10 · Dr.Reddy's 43598-0765-07 · Dr. →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.